In the Original Investigation titled “Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial,”1 published online July 30, 2020, an error appeared in the text. In the Methods section, the age of eligible participants should have been 50 years or older not 50 years or younger. The article has been corrected online.
References
- 1.Khanani AM, Patel SS, Ferrone PJ, et al. Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. Published online July 30, 2020. doi: 10.1001/jamaophthalmol.2020.2699 [DOI] [PMC free article] [PubMed] [Google Scholar]
